You’ve beaten the odds by bringing your product to a successful regulatory approval. Now get ready for the real world- making your product a commercial success. You now have new challenges to face including safety and efficacy data considerations, outcome decisions, risk management issues and post-marketing commitments.
Medpace, long known for its therapeutic and regulatory advantage, has the knowledge to help you find your way.
Medpace has the necessary expertise and ability to conduct Phase IIIb-IV studies in both pharmaceutical and medical device areas.
Our therapeutic and regulatory experts have global operational reach, allowing us to offer full service capabilities that ensure a successful commercial launch of your product.
Medpace is a best-in-class strategic partner for late phase drug and device development programs. Staffed with the industry’s most therapeutically focused leaders, Medpace’s late phase clinical operations teams have expertise in development and trial design best practices, dedicated submissions team to accelerate startup, and noted relationships with key investigative sites, to assure the highest level of quality for outcomes research.
Medpace Late Phase can conduct both interventional and non-interventional type studies:
- Phase IIIb and IV randomized clinical trials
- Observational epidemiologic studies
- Expanded access programs
- Post-authorization safety studies
- Health Economics and Outcomes Research
- Competitive marketing claims studies
Learn more about late phase development. Access slides from Dr. Alex Artyomenko's recent presentation at Outsourcing in Clinical Trials, Europe.
Dr. Alex Artyomenko, Director of Clinical of Operations for Europe and Late Phase Development at Partnerships in Clinical Trials. He presented at the conference on Risk-based Monitoring.
Want to learn more? Contact the Medpace location nearest to you.